Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020

May 2020 | 292 pages | ID: R7846943EB2EN
Global Markets Direct

Abstracts

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus Infections – Pipeline Review, H1 2020, provides an overview of the Respiratory Syncytial Virus Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 10, 2, 50, 23 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 11 and 7 molecules, respectively.

Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Respiratory Syncytial Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Respiratory Syncytial Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Respiratory Syncytial Virus (RSV) Infections - Overview
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Drug Profiles
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abhelix LLC, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics Inc, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advac LLC, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advance Vaccine Laboratories Pty Ltd, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2020
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2020 (Contd..3), H1 2020
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2020 (Contd..4), H1 2020
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2020 (Contd..5), H1 2020
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Abhelix LLC
Abivax SA
ADMA Biologics Inc
Advac LLC
Advance Vaccine Laboratories Pty Ltd
Airway Therapeutics LLC
AlloVir Inc
Anima Biotech Inc
Aridis Pharmaceuticals Inc
Ark Biosciences Inc
Artificial Cell Technologies Inc
AstraZeneca Plc
Atea Pharmaceuticals Inc
Bavarian Nordic A/S
Beijing Advaccine Biotechnology Company Ltd
BioComo Inc
BlueWillow Biologics Inc
BravoVax Co Ltd
Calder Biosciences Inc
Changchun Bcht Biotechnology Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals
Codagenix Inc
Curevac AG
DBV Technologies SA
Enanta Pharmaceuticals Inc
Enyo Pharma SA
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
HanaVax Inc
Heartland Vaccines LLC
Humabs BioMed SA
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immunwork Inc
IMV Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
mAbxience SA
Mapp Biopharmaceutical Inc
Meissa Vaccines Inc
Merck & Co Inc
Moderna Inc
Mucommune LLC
Navigen Inc
NeuClone Pty Ltd
Neuracle Science Co Ltd
Novavax Inc
Pfizer Inc
Phoenix Biotechnology Inc
Pneumagen Ltd
Profectus BioSciences Inc
ReViral Ltd
Riboscience LLC
Ridgeback Biotherapeutics LP
Romark Laboratories LC
Sagimet Biosciences
Sanofi
Shandong Danhong Pharmaceutical Co Ltd
Shionogi & Co Ltd
Sigmovir Biosystems Inc
Signia Therapeutics
TechnoVax Inc
Themis Bioscience GmbH
Trimunocor Ltd
Vault Pharma Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
Visterra Inc
VLP Biotech Inc
Wyvern Pharmaceuticals Inc
X4 Pharmaceuticals Inc
Zhuhai Trinomab Biotechnology Co Ltd